Skip to main content

Market Overview

CVS Downgraded By Vetr


The Vetr crowd on Friday downgraded its rating on CVS Health Corp (NYSE: CVS) from 3.5 Stars to 3 stars and rated the stock a hold. Among the Vetr crowd, 20 percent of users have given CVS a buy rating and 80 percent have a hold rating.

See how crowdsourced ratings could help you time the market.

Vetr’s downgrade coincides with a 4.35-percent increase in CVS’s share price along with an upgrade from Morgan Stanley. Optimism regarding CVS’s proposed acquisition of Aetna has created bullish growth prospects among some analysts.

The Vetr crowd’s target price of $77.11 sits slightly below the current price of $78.27 and well below the average analyst target price of $96.82.


Related Articles (CVS)

View Comments and Join the Discussion!

Posted-In: VetrDowngrades Price Target Analyst Ratings

Latest Ratings

FSRMorgan StanleyMaintains40.0
MEDDA DavidsonMaintains302.0
VICRBWS FinancialMaintains120.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at